Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus

Trial Profile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2011

At a glance

  • Drugs LY 2881835 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Aug 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 09 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top